01—Abstract
Summary
Summary of the 8-K filed May 30, 2024. Cited figures are marked; the original filing is the authoritative source.
Elevance Health, Inc. (ELV) announced on May 29, 2024, the closing of a significant notes offering, raising approximately $2.57 billiona in net proceeds.
This offering included $600 millionb in 5.150% Notes due 2029, $1 billion in 5.375% Notes due 2034, and $1 billion in 5.650% Notes due 2054. The company intends to use these funds for general corporate purposes, including working capital, potential acquisitions, debt repayment, and share repurchases. This financing action provides Elevance Health with substantial liquidity to support its strategic initiatives and financial flexibility.
Investors should note the specific interest rates and maturity dates associated with each tranche of notes, as well as the terms for redemption and potential change of control provisions that could trigger an accelerated repurchase of the notes. The company's ability to continue incurring debt under the indenture provides further operational flexibility.
02—Key points
Key Highlights
- Closed a notes offering totaling $2.57 billion in net proceeds.
- Issued three tranches of senior unsecured notes: $600M (5.150% due 2029), $1B (5.375% due 2034), and $1B (5.650% due 2054).
- Net proceeds will be used for general corporate purposes, including working capital, acquisitions, debt repayment, and share repurchases.
- The indenture does not restrict the incurrence of additional indebtedness by the company or its subsidiaries.
- Notes are subject to optional redemption by the company prior to maturity, with specific call protection periods.
- A change of control event coupled with a credit rating downgrade could trigger a mandatory offer to purchase the notes at 101% of principal.
03—Questions
Frequently Asked Questions
What was the primary purpose of this notes offering?
Elevance Health conducted this notes offering to raise approximately $2.57 billion in net proceeds, which will be used for general corporate purposes. This includes funding working capital needs, potential acquisitions, repaying existing debt (both short-term and long-term), and repurchasing the company's common stock under its share repurchase program.
What are the key terms of the newly issued notes?
The company issued three series of notes: $600 million of 5.150% Notes due 2029, $1 billion of 5.375% Notes due 2034, and $1 billion of 5.650% Notes due 2054. Interest is payable semi-annually on June 15 and December 15, commencing December 15, 2024. The notes have varying redemption terms and include provisions related to change of control events.
Are there any restrictions on Elevance Health taking on more debt after this offering?
According to the filing, the Indenture governing these notes does not prohibit or limit the incurrence of additional indebtedness and other liabilities by Elevance Health or its subsidiaries. This indicates the company retains significant financial flexibility to pursue future financing or operational activities.
What happens if there is a change of control at Elevance Health?
If a change of control occurs and, in addition, a series of these notes is downgraded below an investment grade rating by Moody's, S&P, and Fitch within a specified period, Elevance Health will be required to make an offer to purchase all of the notes of that affected series at 101% of their principal amount, plus accrued interest.
04—Continue